C-IT Neo: interim results of neoadjuvant ipilimumab & nivolumab in melanoma

Sarah Lochrin, MBBCh, Memorial Sloan Kettering Cancer Center, New York, NY, discusses interim results from the Phase II C-IT Neo trial (NCT05658941) of single dose neoadjuvant ipilimumab plus nivolumab in patients with resectable stage IIIB-IV melanoma. The regimen achieved a favorable rate of major pathologic responses, and CD8-targeted PET imaging correlated with CD8+ infiltration on pathology, though not with response outcomes. These findings support continued investigation into single-dose neoadjuvant immune checkpoint blockade and imaging-based biomarkers. This interview took place during the 2025 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.